Govt Job: Walk in interview for Pharmacist at PGIMER

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

Post : Pharmacist

Project Title : A PHASE 2/3, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE SAFETY AND IMMUNOGENICITY OF COVOVAX [SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS- CoV-2 rS) WITH MATRJX-M1 ™ ADJUVANT| IN INDIAN ADULTS AGED > 18 YEARS AND CHILDREN AGED 2 TO 17 YEARS

Qualification : Essential B.Pharma / Diploma in pharmacy from a recognized institution / board, should be a registered pharmacist under the pharmacy act 1948 – Minimum 1 year of experience in dispensing and /or storage and dispensing of drugs in a reputed hospital or institution or in a drug stores of a pharmaceutical concern / Clinical research experience.

Tenure : 3 months

Salary : 33,300/-

Date of Interview : 03rd  September,2021 (Friday)

Time of Interview : 03:00 pm

Selection Process :  An online interview will be conducted on 03ri1 September 2021 at 3:00 PM via zoom/Google meet. In view of C-19, no face to face Interview will be conducted.

How to apply : Interested candidate should email their applications along with their curriculum vitae (softcopy of resume) with supporting documents address to Dr, Madhu Gupta, Professor on email ID : covovax2021@gmail.com

Last date: before 05:00 PM dated 31/08/2021. No applications will be entertained after 05:00 PM on 31/08/2021

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March